Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
17 nov. 2021 17h00 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
22 oct. 2021 09h55 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the...
Biofrontera reports preliminary approximate revenues for the month of September 2021
01 oct. 2021 07h44 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera reports preliminary revenue for the month of August 2021
08 sept. 2021 12h10 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera provides update on clinical developments
22 juin 2021 09h00 HE
|
Biofrontera AG
Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
Biofrontera reports preliminary revenue for the month of May 2021
07 juin 2021 10h01 HE
|
Biofrontera AG
Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera reports preliminary revenue for the month of April 2021
06 mai 2021 07h23 HE
|
Biofrontera AG
Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
26 févr. 2021 09h20 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Biofrontera submits study report of pharmacokinetics study to FDA
24 févr. 2021 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the...
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
02 févr. 2021 10h35 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical...